[ad_1]
A report from an English newspaper The Guardian (in English) reported on Friday (12/25) that the pharmaceutical company AstraZeneca, in alliance with University of London, study a new road what can prevent symptoms of an infection by COVID-19. The company has already registered for testing in the United States.
It is important to remember that the company is already working, in partnership with the University of Oxford, on the design of a vaccine against COVID-19.
In theory, the remedy, called AZD7448, could prevent a person from having symptoms of a COVID-19 infection for up to 12 months, provided they have taken the drug for up to eight days after exposure. to the virus.
Unlike the natural antibody response produced by the vaccine, the expectation is that the drug will cause “instant immunity” against the symptoms of COVID-19 infection by creating antibodies in the laboratory. The drug would be used in emergency treatments, such as healthcare professionals and nursing home users and employees, for example.
The tests, so far, have been conducted in London and 100 other locations around the world. In the land of Rainha, the drug has been applied to two-dose cocktails in volunteers and test participants. AstraZeneca’s expectation that if the country’s regulatory agencies publish, the drug could already be available for production in April 2021.
